CS260968B1 - A method for producing human leukocyte interferon - Google Patents

A method for producing human leukocyte interferon Download PDF

Info

Publication number
CS260968B1
CS260968B1 CS843139A CS313984A CS260968B1 CS 260968 B1 CS260968 B1 CS 260968B1 CS 843139 A CS843139 A CS 843139A CS 313984 A CS313984 A CS 313984A CS 260968 B1 CS260968 B1 CS 260968B1
Authority
CS
Czechoslovakia
Prior art keywords
kpobh
πρκ
mhhyt
separating
ammonium chloride
Prior art date
Application number
CS843139A
Other languages
Czech (cs)
Other versions
CS313984A1 (en
Inventor
Leonid P Korobicyn
Anatolij M Pivovarov
Svetlana V Goncarova
Irina N Kulikova
Jurij V Tjagotin
Original Assignee
Leonid P Korobicyn
Anatolij M Pivovarov
Svetlana V Goncarova
Irina N Kulikova
Jurij V Tjagotin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leonid P Korobicyn, Anatolij M Pivovarov, Svetlana V Goncarova, Irina N Kulikova, Jurij V Tjagotin filed Critical Leonid P Korobicyn
Priority to CS843139A priority Critical patent/CS260968B1/en
Publication of CS313984A1 publication Critical patent/CS313984A1/en
Publication of CS260968B1 publication Critical patent/CS260968B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Řešení se týká oblasti průmyslové biologie, Způsob výroby lidského leukocytárního interferonu spočívá v odstředění krve dároe, oddělení leukooytů, hemolýze zbývajících erytrocytň s chloridem amonným resuspendování usazených leukooytů v živném prostředí podle Eagla a oddělení cílového produktu. Přínosem jg, že odstředění použité krve se uskutečňuje při 1500 až 5000 g po dobu 35 až 45 minut, odebrání 30 až 75 % objemu vrohní části leukooyty obsahující erytrooytové hmoty, hemolýza se provede roztokem 0,80 až 0,84 chloridu amonného při poměru 1 t /3 až 50/.The solution relates to the field of industrial biology. The method of producing human leukocyte interferon consists in centrifuging donor blood, separating leukocytes, hemolysis of the remaining erythrocytes with ammonium chloride, resuspending settled leukocytes in a nutrient medium according to Eagle and separating the target product. The advantage is that the centrifugation of the used blood is carried out at 1500 to 5000 g for 35 to 45 minutes, removal of 30 to 75% of the volume of the upper part of the leukocyte containing erythrocyte mass, hemolysis is carried out with a solution of 0.80 to 0.84 ammonium chloride at a ratio of 1 t /3 to 50/.

Description

ΟΠΗΟΑΗΗΕ H3OBPETEHHH K ABTOPCKOMY CBHflETEJlbCTBY 3aHBjieHo: 20,08.81 3a«BKa #> 3337658/28-13 MKH3 A 61 K 45/02

Abtopw: Jl.n.Kopo6HHbiH, Α.Μ.Πηβοβθροβ, C.B.roHHaposa, H.H.KynHKQBaη ΙΟ,Β.Τηγοτηη

3aaBHTenb: Bcčcoioshmh HayHHo-HccnenoBaTenbCKHň HHCTHTyT oco6o nHCTtix 6ho-npenapaTOB

HaaBaHne Η3θ6ρετβΗΗΗ: CIIOCOB ΠΟΠΠΕΗΗΗ HEJIOBEHECKOrO ΠΕίΙΚΟΙίΗΤΑΡΗΟΓΌ HHTEP-ΦΕΡΟΗΑ Η3θ6ρεΤβΗΗβ OTHOCHTCH Κ oCíiaCTH npOMbnnneHHOft 0ΗθηθΓΗΗ, a ΗΜβΗΗΟ κ cnoco-6aM nojiyMeHHH ΗΗτερφβροΗβ M3 jieftKOííHTQB kpobh qefloBeKa. H3BecTeH cnoco6 nonyneHHH jieftKOnírrapHoro Ηκτερφεροκβ nyTeM BbiflenoHHH něňKOUjHTOB, HHflyKllHH HHTep4)epOHOO6pa3OBaHHB, 0HOCHHTe3a ΗΗΤβρφθρθΗ3,, BblflejieHHHΗΗΤ.βρφερθΗ3 (1). ΟΛΗβκο Bbixofl κηετοκ cocTaBJíaeT 10-1512 ot nonynanHH ηεδκσηΗτοΒ, co«epxa-mHXCH B UeJIbHOÍi KPOBH» lÍ3BecTeH Tam cnocoS nonyneHHH HenoBenecKOro neŇKonHTapHoro ΗΗτβρφεροκβnyTeM uenTpi^yr:npoBaHH« nottopcKOň KpOBH, oŤefleneHHH ηεϋκοηΜΤΟΒ, neMonnsa ocTaTouHbix 3pnTpou;HTOB xjiophctmm ημμοηηθμ, pecycneHRHpOBaHHH ocajjKa ηεκκοηΗ-tob b nHTaTenbHoň cpene Hrna, BMnenéHHH neneepro npoflyiera (2),

OflHaKO BbIXOfl ΜΗΤβρφβρΟΗβ Ηβ3Η3ΗΗΤεηβΗ H COCTaBJIHST 4*10ť ME/n C eflHHHUbloĎteMa nepepaSaTbiBaeMOň KpOBH.

Uenbio Η3θ6ρετβΗΗΗ HBnneTCH noBbnueHHe Bbrxona ueneBoro npoflyKTa.yKaaaHHaH u,enb nocTHraeTCH τβΜ, ητο πρκ ocymecTBneHHH cnoco6a nonyHěHHH

uenoBeuecKoro πβήκομΗτερΗΟΓΟ ΗΗτβρφβροΗβ nyTeM ^eHτpHφyΓHpoBaHHH noHopcKoňKpOBH, OTfleJieHHB JieftKOUHTOB, reMOÍIH3a OCTaTOHHbIX SpHTpOnHTOB XnOpMCTbIM aM —μοηηθμ, pecycneHflHpoBaHHH ocaflKa πεήκοηκτοΒ b nHTaTenbHoň cpene Hrna, Bbine-neHHH neneBoro nponyKTa oTJiHHHTenbHoň ocoGeHHocTbio nenaerca το, hto neHTpH-φyΓHpoBa^^He nenbHoň kpobh ocymecTBnjnoT πρκ 1500-5000g b TeneHHe 35-45 MHHyT 260968 OTĎHpaioT 30-75% οδτ,εΜρ Bepxaeň uacra neHKOHHTcopepJKaiiíeň sphtpouhthoh Maccbi,reMOjiH3 ocymecTBJíHWT 0,80-0,842! pacTBopoM xnopHpa βμμοηηη tipu cooTHonieHHH1:(3-50).

Cnoco6 nOHCHHeTCH CJieflywmHMH npHMepaMH. ΠρΗΜβρ 1

KpoBb flOHopoB co6HpamT b njiacTHKOBbie πβκετΜ, coflepjKanme pHTpaTHbiň CTa6n-jiH3aTop. Cpa3y nocne c6opa KpoBb yeHTp^yrHpyioT np« 4°C b τεπεΗΗε 20 MHHyTπρπ 2000g, πτο6μ οτρεηΗΤΒ nna3My ot sphtpohhtob. nocne ypaneHHH njia3MM co6h-patoT 10-15 mji Buf fy coaf, nepeHocHT ero b προ6κρκΗ, οορερκβπριε 1 mji pacTBo-pa 3THJieHflnaMHHTeTpaaueTaTa (3flTA) h pccýcneHpHpytoT* ČMecb BbipepKHBaroT ' 10 MHHyT npH +4°C h ueHTpH<|>yrHpyiOT πρπ 160g b τεηεΗΗε 10 mhh. OcapoK πείίκο-HHTOb peeycneHflHpyioT b ,0 mji nHTaTenbHoň cpepbi Hrna MEM, copcpwameH 10% ue-noBeuecKoň α,ίΒοροτκκ. K nonyueHHofí cycneH3HH κηετοκ po6aBnnmT 1/10 oSteMa3ΠΤΑ h cycneH3Hio CMeiiiHBaioT c 8 ofiteMaMH 0,83% NH^Cl. Περε3 HecKonbKO MHHyTcMecb ueHTpH$yrHpyioT πρκ 1 60g b τεηεΗκε 10 MHHyT. nonyneHHbiH ocaflos πεήκο-Hhtob pecycneHflHpyioT b cBe»eň nHTaTenbHoň cpepe Hrna MEM no KOHeuHoň koh-

1 nHTpa kpobh ηπη 15% οτ toto KonnuecTBa πεήκορΗτοΒ, κοτοροε copepacHTca βflOHOpCKOH κροΒΗ.

JleňKopHTbi, pecycneHnHpoBaHHbie β πητβτθπβηοη cpepe Hrna, o6pa6aTbiBaroT200 ΜΕ/μπ neňKOHHTapHoro nenoBenecKoro ΗΗτερφεροΗβ πρκ 37°C b τεηεΗκε 2 na-cob. 3aTeM κ cycneH3HH πεκκορΗΤΟΒ poSaBnnioT HHpyKTop-BHpyc 6one3HH HbKncact-na ηπη BHpyc CeHpaň b po3e 20-25 HHKToToKCHnecKHX po3 Ha 1 KneTKy h HHKy6H-pyioT eme β τεπεΗΗε 1 naca npH 37’C. Πο HCTeneHHH 3Toro BpeMeHH HeapcopOupo-BaHHbiň Ha κηετκεχ BHpyc οτρεπΗίοτ neHTpH<J>yrHpoBaHHeM πρκ 600g b τεηεΗΗε115 MHHyT. IIonyueHHbiň ocapoK κηετοκ pecycneHflHpyioT b nHTaTenbHoň cpepe HrnaMEM β κοΗεηΗΟΗ KOHneHTpapHH 5—10χ10β κπ/μπ. nHTaTenbHan cpepa copepxHT 5%ηεηοΒεηεοκοΗ nna3Mbi, CycneH3Hic κηετοκ HHKyČHpawT πρκ 37 °C πρπ περεΜειΠΗΒβΗΗΗb tchghho 16-20 qacoB. Πο 33ΒεριπεΗΗΗ yKaaaHHoro cpOKa KynbTypanbHyio wHpKocTb οτρεηΗΐοτ οτ κηε-τοκ-npopypeHTOB qeHTpH&amp;yΓΗροΒΗΗκεΜ πρκ 1500g β τεηεΗΗε 30 MHHyT. OcapoKκηετοκ OTGpacbiBawr, a KynbTypanbHyw )KHp,KOCTb BbipepacHBamT β τεηεΗκε 3-4 cy-tok npH +4eC h pH pacTBopa, poBepeHHoro no 2,5 1 h HC1 c penbw ηηηκτηβηρηηBHpyca-HHflyKTopa, a 33τεΜ β Heň προΒορητ onpeperteHne THTpa ΗΗτερφεροΗΗ. A6conioTHHH Bbixofl ΗΗτερφεροΗβ c 1 nHTpa κροΒΗ pocraraeT 4*10* ME. ΠρκΜερ 2

KpoBb coSHpawx b nnacTHKoshie naKGThi THna "ΓεΜεκοκ", σορερχειπρο ρκτρετΗΜΗCTa6HnH3aTop, Cpa3y nocne c6opa KpoBb ^GHτpHφyΓHpy^oτ πρκ 2000*100g β τεηεΗΗε40-5 MHHyT πρκ +4σΟ· c penbw οτρεηεΗΗΗ nnasMbi οτ sphtpophtob. Ποοηε ypaneHHHnna3Mbi co6Hparar bgpxhhg 2/3 o6T>GMa 3pHTpopHTapHoň Maccbi h pecycneHpHpyioT β3 oStGMax 0,83 NK4C1. Cmocb peHTp^yrHpyroT npH 500g β τεηεΗκε 40 MHHyT. Πο- , nynGHHbiH ocaflOK κηετοκ pecycneupHpyjoT β 10 oĎteMax 0,83% NH4C1 h peHTpH^iy-, rHpyioT πρκ 150g β τεπεκκε 20 MHHyT. nonyneHHbift ocaflOK πείίκορΗτοΒ pecycnenpH- pyioT β ΠΗτβτεηϊιΗΟΗ cpepe Hrna MEM, copep»améit 4% nenoBenecKoň cbibopotkh bkohchhoh KOHHOHTpapHH 10y κπ/μπ', Βωχορ ηεήκορΗΤΟΒ cocTaBnaeT 5,0χ10β κπετοκc 1 nHTpa κροΒΗ ηπη 80% οτ hx copepJKaHHH b penbrioň kpobh, HHpyKpHio h 6hochh-T03 HHTODdlGOOHa ΠΡΟΒΟΠΗΤ TBK JKO IOK Β ΠΡΗΜΒΡΒ 1 .

KpoBb οτ poHOpoB co6HparoT b nnacTHKOBbie πβκετΜ THna "ΓεΜεκοη", copepaca-ηιηθ pHTpaTHbiň cTa6HHH3aTop. Cpa3y nocne c6opa kpobh ρεΗτρΗφνΓΗργιοτ npH 2000-lOOg β · τεπεΗΗε 40-5 MHHyT npH +4’C c penbw οτρεηεΗΗΗ nna3Mbi οτ 3ριιτρορΗΤθΒ. 260968 nocne yflaneHHH rinaaMbi co6npa»T BepxHHe 2/3 oSteMa spHTpoflHTapHoň Maccbi h pe-cycneHflHpyioT b 25 o&amp;beMax 0,83% NH^CI.h u;eHTpn4)yrnpyKT πρκ 250g b TeneHHe20 MHHyTe IlonyqeHHbiH ocafloK κπετοκ pecycneHflHpyroT b 3 oSteMax 0,80% NH^Cl hUeHTpH$ympyroT πρκ 150g b leúeHae 20 MHHyr. nonyneHHbiň ocanox neňKOflHTOB pe-cyčneHflupyioT b πητθτθπβηοη cpefle Hrna MEM, coflepxameň 4% HenoBenecKoň cmbo-POTKH B KOHeHHOňAKOHfleHTpaflHH 10 ΚΠ/ΜΠ. BblXOfl neňKOflHTOB COCTaBnHeT 5x10κπετοκ c 1 nHTpa kpobh ηπη 80% οτ hx očmero coflepaiaHHH b flenbHOň kpobh. Hh-flyKflHIO H 6HOCHHTe3 ΗΗΤβρφβρΟΗΗ npOBOflHT ·Τ3Κ »e K3K B npHMepe 1. A6cOJIIOTHb!H BblXOfl ΗΗΤβρφβρΟΗβ C 1 nHTpa KpOBH COCTaBnHeT 12 *10* ME. ÍIpHMep 4.

KpoBb οτ flOHopoB coČHpároT b nnacTHKOBbie naxeTbi Tuna ''TeMaKOH", coflepacaflHeUHTpaŤHbiň eTa6KrtH3aTop, Cpaay nocne c6opa xposb u,eHTpn(i)yrHpyioT πρκ 2000 -tlOOg b τεηβΗΗβ 40í5 MHHyT πρκ +4*C c nenbio OTfleneHHH nna3Mbi οτ apHTpoflHToB.Ilocne yflaneHHH nna3Mbi co6npaioT BepxHHe 2/3 oCteMa spHTpoflHTapHoň Maccbi h pe-cycneHflHpyroT b 50 oS-beMax NE^Cl. CMecb BbiflepscHBaror 10 MHHyT npH +4eC h fleHT-(JjyrHpyioT npH 150g b TeneHne 20 MHHyT. nonyneHHbiň ocapoK κπετοκ pecycneHflHpy-roT b ΠΗΤβτεπΒΗοή cpep;e Hrna MEM, coflepacameň 4% nenoBenecKoň cmbopotkh, b ko-HenHoft KOHii;eHTpau;HH 10? κπ/μπ. Bbixofl neňKOflHTOB cocTaBnneT 4*10-^ κπετοκ c1 nHTpa kpobh ηπη 70% οτ hx coflepoKaHHH b nenbHoň kpobh. HHflyKflHio h 6hochh-τε3 ΗΐιτερφεροΗΗ προβοαητ TaK we KaK b npHMepe 1 i 6 ASconioTHbiří Bbixofl ΗΗτερφεροΗβ< c 1 nHTpa kpobh cocTasnaeT 8x10 ME. ΠρΗΜβρ 5

KpoBb οτ flOHopoB coSHparoT b nnacTHKOBbie πβκετΜ Tnna "ΓβΜβκοΗ1’, coflěpacaflHeAHTpaTHbiň cTa6nnH3aTop. Cpaay nocne oTÓopa κροββ ΗεήτρΗφντΗρνιοτ πρκ 1500gb τεηεΗΗβ '90 mhh. πρκ 4°C c nenbro OTfleneHHH nna3Mbi οτ spHTpoflHTOB. nocneyflaneHHH nna3Mbi coĎHpawT BepxHHe 75% o6beMa apHTpoflHTapHoň Macau h peeycneH-flnpyioT ee b 3 o&amp;beMax 0,84% NH4CI, BbiflepwHBakiT CMecb npH +4tfC 20 MHHyT hfleHTpHpyioT npH 250g β τεηεΗΗε 20 MHHyT. nonyneHHbrfí ocafloK neňKOflHTOB pecyc-neHflHpyioT b 20 o6-beMa. 0,84% NH4CI, μεΗΤρΗφνΓΗρνιοτ npH 150g β τεηβΗΗθ20 MHHyT. OcaflOK neňKOflHTOB pecycneHflHpyroT b riHTaTenbHoň cpefle flo KOHeflfloňKOHfleHTpaflHH 10? κπ/μπ. Bbixofl neňKOflHTOB cocTaBnneT 3χ10* κπετοκ c 1 nHTpakpobh ηπη 50% οτ o6mero coflepacaHHH β αθηβηοη kpobh. HHflyKflHio η 6nocHHTe3ΗΗτερφεροκε προβοαητ τθκ we KaK β npHMepe 1. 6 A6conioTHbiíí Bbixofl ΗΗτερφεροΗ3 c 1 niiTpa kpobh cocTaBnneT 6x10 ΜΕ. ΠρΗΜβρ 6

KpoBb οτ flOHopoB coĎHpaioT β nnacTHKOBbie naxeTbi THna nreMaKOH", coflepaca-mne RHŤpaTHbiň cTa6nnH3aTop. Cpaey nocne c6opa KpoBb ΑβΗτρκφνΓΗρνιοτ πρκ5000g β τεηεΗΗε 10 MHHyT npH 4*0 c flenbio OTfleneHHH tina3Mbi οτ apHTpoflHTap- HOň Maccbi. nocne yflaneHHH nna3Mbi co6Hparor BepxHHe 30% oSteMa spHTpoflHTapHoň

Maccbi h pecycneHflHpyroT β 3 o&amp;beMa. 0,80% NH^Cl, ΑβΗτρκφνΓΗρνιοτ ripn 250g bTeneHHe 20 MHHyr h ocafloK neňKOflHTOB pecycneHRHpyioT ποΒτορΗΟ b 10 oCteMax0,83% NH^Cl. JleftKÓflHTbi ocaacflawT ΑβΗτρκφνΓΗροΒβΗΗεΜ πρκ 150g b Tenemie 20 MH-HyT h pecycneHflHpyroT b nHTaTenbHOň cpefle.'Bbixofl neňKOflHTOB c 1 nHTpa kpobhcoc.TaBnneT ,5 xlO9 κηβτοκ ηπη 80% οτ hx osmero coflepacaHHH b flenbHOň kpobh.HHflyKflHio η 6ηοοηητθ3 ΗΗΤβρφβροΗβ προβοαητ tak ace KaK β npHMepe 1. A6conroTHbiň BbiKpfl ΗΗΤβρφβροΗβ c 1 nHTpa kpobh cocTasnaeT 3xlOe ME,npeflnoMeHHbiň cnoco© πο3Βθππβτ hobmchtL· Bbixofl fleneBoro npoflyKTa flo 10- 12*· l0tf ME/n KpOBH ΠΟ CpaBHeHHIO C HSBeCTHblM CnOCOSOM 4'10* ME/Λ KpOBH.

ΦΟΡΜΥΕΑ H30BPETÉHHH «

Cnoco6 nonyneHHH HenosenecKoro neňKoflHTapHoro ΗΗτερφεροΗβ nyTGM ιχβΗτρΗ-^yrHpoeaHHH flOHopcKoň kpobh, OTfleneHHH neňKOflHTOB, reMonH3a ocTaroMHbix 260968 -4- apHTpoqHTOB xnopucTbiM θμμοηηθμ, pecycneHflHpoBaHHH ocaflKa neňKOflHŤOB b πητη—TenbHoň cpefle Hrna, BbifleneHHH neneBoro npoflyKTa, OTnHnatomHňcH τβΜ, ητο, cuejibio noBbnueHHB Bbixofla peneBoro npoflyKTa, iíeHTpmjjyrupoBaHHG penbHoíí kpobhocymecTBjíHioT πρκ 1500-5000g b TeneHHe 35-45 MHHyT, oT6nparoT 30-75% o6i>eMaBepxHeft nacTH ňeňKOflHTCoflepxcameň apHTpouHTHoň Maccbi, reMonH3 ocymecTBnntoT0,80-0,84% pacTBopoM xnopHfla ημμοηηη πρκ cooTHomeHHH 1:(3-50). HCTOHHHKH ΗΗφορΜΗΐχΗΗ, npHHHTbie BO BHHMaHHe πρκ 3KcnepTH3e: 1. AHanor-ConoBbeB B.fl., ΕβκτβΜΗροΒ Γ.Α. "ΗϋτερφβροΗ b τεορκπ h npaKTHKeMeflHyHHbí", M. , 1970. 2. ΠροτοτΗΠ In: Human Interferon Kauppinen H.-U., Myllyly'' G,, - 6, 1978p. 1-13.

P E Φ E P A T

CnOCOE ΠΟΗΥΗΕΗΗΗ HEJIOBEHECKOrO ΠΕΗΚΟΗΗΤΑΡΗΟΓΟ ΗΗΤΕΡΦΕΡΟΗΑ

HacToainee Η3θ6ρετβΗΗε othochtch k oSnacTH npoMbmmeHHoft ©ηοπογηη.

CnocoS nonyneHHH nenoBenecKoro neňKopHTapHoro ΗΗτερφθροΗΗ coctoht b fleHT p^yrHpoBaHHH ROHopcKoň kpobh, oT/jejieHHH JieňKouHTOB, reM0JiH3e ocTaTonHbixSpHTpOflHTOB XflOpHCTbIM aMMOHHeM, pecycneHflHpOBaHHH ocaflKa neňKOflHŤOB B ΠΗΤ3-TenbHoň cpefle Hrna, BbifleneHHH peneBoro npoflyKTa, Hobmm ΗΒηπετοΗ το, ητοΗεΗτρκφνΓΗροΒ3Ηκβ HenbHoň kpobh ocyinecTEnnioT πρκ 1500-5000g b TeneHHe 35-45 MHHyT, oTSHpaiOT 30-75% oSteMa BepxHeft nacTH neňKOflHTCoflep®ameft spHTpoflHT·I hoh Maccbi, reMonH3 . ocymecTBnntoT 0,80-0,84% pacTBopoM xnopnfla ημμοηηη πρκjcooTHomeHHH 1:(3-50). IIpH3HaHo H3o6peTeHHeM no pe3ynbraTaM 3KcnepTH3bi, ocymecTBneHHoft FocypapcT-BeHHbíM ΚοΜΗΤβτοΜ CCCP nó .nenaM H3o6peTeHHň η οτκρΜτκή, 260968

3ΠΗΟΑΗΗΕ H3OBPETEHHH K ABTOPCKOMY CBHflETEJlbCTBY 3aHBjieHo: 20,08.81 3a «BKa #> 3337658 / 28-13 MKH3 A 61 K 45/02

Abtopw: Jl.n.Kopo6HHbiH, Α.Μ.Πηβοβθροβ, CBroHHaposa, HHKynHKQBaη ΙΟ, Β.Τηγοτηη

3aaBHTenb: Bcčcoioshmh HayHHo-HccnenoBaTenbCKHn HHCTHTyT oco6o nHCTtix 6ho-npenapaTOB

HaaBaHne Η3θ6ρετβΗΗΗ: CIIOCOB ΠΟΠΠΕΗΗΗ HEJIOBEHECKOrO ΠΕίΙΚΟΙίΗΤΑΡΗΟΓΌ HHTEP-ΦΕΡΟΗΑ Η3θ6ρεΤβΗΗβ OTHOCHTCH Κ oCíiaCTH npOMbnnneHHOft 0ΗθηθΓΗΗ and ΗΜβΗΗΟ κ Cnoc-6am nojiyMeHHH ΗΗτερφβροΗβ M3 jieftKOííHTQB kpobh qefloBeKa. H3BecTeH cnoco6 nonyneHHH jieftKOnRrapHoro Ηκτερφεροκβ nyTeM BbiflenoHHH ň HT OB OB OB OB OB, HHflyKllHH HHTep4) epOHOO6pa3OBaHHB, 0HOCHHTe3a ΗΗΤβρφθρθΗ3 ,, BblflejieHHHΗΗΤ.βρφερθΗ3 (1). ΟΛΗβκο Bbixofl κηετοκ cocTaBJíaeT 10-1512 rpm nonynanHH ηεδκσηΗτοΒ what «epxa-mHXCH B UeJIbHOÍi KPOBH» lÍ3BecTeH There cnocoS nonyneHHH HenoBenecKOro neŇKonHTapHoro ΗΗτβρφεροκβnyTeM uenTpi ^ yr: npoBaHH «nottopcKOň KpOBH, oŤefleneHHH ηεϋκοηΜΤΟΒ, neMonnsa ocTaTouHbix 3pnTpou; HTOB xjiophctmm ημμοηηθμ, pecycneHRHpOBaHHH ocajjKa ηεκκοηΗ -tob b nHTaTenbHoň cpene Hrna, BMněHHH neneepro npoflyiera (2),

BbIXOfl ΜΗΤβρφβρΟΗβ Ηβ3Η3ΗΗΤεηβΗ H COCTaBJIHST 4 * 10ť ME / n C eflHHHUbloĎteMa nepepaSaTbiBaeMoň KpOBH.

Uenbio θ3θ6ρετβΗΗΗ HBnneTCH noBbnueHHe Bbrxona ueneBoro npoflyKTa.yKaaaHHaH u, enb nocTHraeTCH τβΜ, ητο πρκ ocymecTBneHHH cnoco6a nonyHeHHH

uenoBeuecKoro πβήκομΗτερΗΟΓΟ ΗΗτβρφβροΗβ rivet ^ eHτpHφyΓHpoBaHHH noHopcKoňKpOBH, OTfleJieHHB JieftKOUHTOB, reMOÍIH3a OCTaTOHHbIX SpHTpOnHTOB XnOpMCTbIM aM -μοηηθμ, pecycneHflHpoBaHHH ocaflKa πεήκοηκτοΒ b nHTaTenbHoň cPen Hma, Bbine-neHHH neneBoro nponyKTa oTJiHHHTenbHoň ocoGeHHocTbio nenaerca το, HTO-neHTpH φyΓHpoBa ^^ Ile nenbHoň kpobh ocymecTBnjnoT πρκ 1500- 5000g b TeneHHe 35-45 MHHyT 260968 OTDHpaioT 30-75% οδτ, εΜρ Bepxaen uacra neHKOHHTcopepJKaiiien sphtpouhthoh Maccbi, reMOjiH3 ocymecTBJiHWT 0,80-0,842! pacTBopoM xnopHpa tip cooTHonieHHH1: (3-50).

Cnoco6 nOHCHHeTCH CJieflywmHMH npHMepaMH. ΠρΗΜβρ 1

KpoBb flOHopoB co6HpamT b njiacTHKOBbie πβκετΜ, coflepjKanme pHTpaTHbien CTa6n-jiH3aTop. Cpa3y nocne c6opa KpoBb yeHTp ^ yrHpyioT np «4 ° C in 20 MHHyTπρπ 2000g, in 6μ οτρεηΗΤΒ nna3My ot sphtpohhtob. nocne ypaneHHH njia3MM co6h-np 10-15 patoT Buf fy coaf, nepeHocHT ero προ6κρκΗ b, vk pacTBo οορερκβπριε 1-pa 3THJieHflnaMHHTeTpaaueTaTa (3flTA) h * pccýcneHpHpytoT ČMecb BbipepKHBaroT '10 MHHyT NPH + 4 ° C h ueHTpH <|> yrHpyiOT πρπ 160 g b τεηεΗΗε 10 mhh. OcapoK-HHTOb peeycneHflHpyioT b, 0 mji nHTaTenbHoň cpepbi Hrna MEM, copcpwameH 10% ue-noBeuecKoň α, ίΒοροτκκ. K nonyueHHofí cycneH3HH κηετοκ po6aBnnmT 1/10 oSteMa3ΠΤΑ h cycneH3Hio CMeiiiHBaioT c 8 ofMaMH 0.83% NH4 Cl. Περε3 HecKonbKO MHHyTcMecb ueHTpH $ yrHpyioT πρκ 1 60g b τεηεΗκε 10 MHHyT. nonyneHHbiH ocaflos πεήκο-Hhtob pecycneHflHpyioT b cBe »e nHTaTenbHoň cpepe Hrna MEM no KOHeuHoň koh-

1 nHTpa kpobh ηπη 15% οτ this KonnuecTBa πεήκορΗτοΒ, κοτοροε copepacHTca βflOHOpCKOH κροΒΗ.

JleňKopHTbi, pecycneHnHpoBaHHbie β πητβτθπβηοη cpepe Hrna, o6pa6aTbiBaroT200 ΜΕ / μπ neňKOHHTapHoro nenoBenecKoro naτερφεροΗβ πρκ 37 ° C b τεηεΗκε 2 na-cob. 3aTeM κ cycneH3HH ε κ S S S H H H H H B py -25 -25 -25 -25 -25 -25 na -25 -25 -25 -25 H H H H H H H H H H H H -25 -25 -25 -25 -25 -25 -25 -25 -25 -25. Πο HCTeneHHH 3Toro BpeMeHH HeapcopOupo-BaHHbi Ha ε η HT H H H H H H H H g g g g g g g g g g g g g g. IIonyueHHbiB oapoK κηετοκ pecycneHflHpyioT b nHTaTenbHoň cpepe HrnaMEM β κοΗεηΗΟΗ KOHneHTpapHH 5 - 10χ10β κπ / μπ. nHTaTenbHan cpepa copepxHT 5% ηεηοΒεηεοκοΗ nna3Mbi, CycneH3Hic κηετοκ HHKyČHpawT πρκ 37 ° C πρπ περεΜειΠΗΒβΗΗΗb tchghho 16-20 qacoB. Πο 33ΒεριπεΗΗΗ yKaaaHHoro cpOKa KynbTypanbHyio wHpKocTb οτρεηΗΐοτ οτ κηε-τοκ-npopypeHTOB qeHTpH &amp; yΓΗροΒΗΗκε πρκ 1500g β τεηεΗΗε 30 MHHyT. OcapoKκηετοκ OTGpacbiBawr and KynbTypanbHyw) KHP, KOCTb BbipepacHBamT β τεηεΗκε 3-4 cy-flow NPH + 4EC h pH pacTBopa, but poBepeHHoro 2.5 1 HC1 c h penbw ηηηκτηβηρηηBHpyca-HHflyKTopa and 33τεΜ β Hen προΒορητ onpeperteHne THTpa ΗΗτερφεροΗΗ. A6conioTHHH Bbixofl ΗΗτερφεροΗβ c 1 nHTpa κροΒΗ pocraraeT 4 * 10 * ME. ΠρκΜερ 2

KpoBb coSHpawx b nnacTHKoshie naKGThi THna, Cpa3y nocne c6opa KpoBb ^ GHτpHφyΓHpy ^ oτ πρκ 2000 * 100g β τεηεΗΗε40-5 MHHyT πρκ + 4σΟ · c penbw οτρεηεΗΗΗ nnasMbi οτ sphtpophtob. Ποοηε ypaneHHHnna3Mbi co6Hparar bgpxhhg 2/3 o6T> GMa 3pHTpopHTapAn Maccbi h pHyPHpyioT β3 oStGMax 0.83 NK4C1. Cmocb peHTp ^ yrHpyroT npH 500g β τεηεΗκε 40 MHHyT. Πο-, nynGHHbiH ocaflOK κηετοκ pecycneupHpyjoT β 10 μMM 0.83% NH4C1 h peHTpH ^γy-, rHpyioT πρκ 150g β τεπεκκε 20 MHHyT. nonyneHHbift ocaflOK πείίκορΗτοΒ pecycnenpH- pyioT β ΠΗτβτεηϊιΗΟΗ CPEP Hma MEM copep »Ameitech 4% nenoBenecKoň cbibopotkh bkohchhoh KOHHOHTpapHH 10y κπ / μπ 'Βωχορ ηεήκορΗΤΟΒ cocTaBnaeT 5,0χ10β κπετοκc 1 nHTpa κροΒΗ ηπη 80% οτ hx copepJKaHHH penbrioň kpobh b, h HHpyKpHio 6hochh -T03 HHTODdlGOOHa TBK JKO IOK J ΠΡΗΜΒΡΒ 1.

KpoBb οτ poHOpoB co6HparoT b nnacTHKOBbie πβκετΜ THna "ΓεΜεκοη", copepaca-ηιηθ pHTpaTHbien cTa6HHH3aTop. Cpa3y nocne c6opa kpobh ρεΗτρΗφνΓΗργιοτ npH 2000-100g β · τεπεΗΗε 40-5 MHHyT npH + 4'C c penbw οτρεηεΗΗΗ nna3Mbi οτ 3ριιτρορΗΤθΒ. 260968 nocne yflaneHHH rinaaMbi co6npa »T BepxHHe 2/3 oSteMa spHTpoflHTapMoon Maccbi h pe-cycneHflHpyioT b 25 o &amp; beMax 0.83% NH ^ CI.hu; eHTpn4) 80% NH4 Cl hUeHTpH $ ympyroT πρκ 150g b leuHe 20 MHHyr. nonyneHHbiň ocanox neňKOflHTOB pe-cyčneHflupyioT b πητθτθπβηοη cpefle Hrna MEM, coflepxameň 4% HenoBenecKoň cmbo-POTKH B KOHeHHOňAKOHfleHTpaflHH 10 ΚΠ / ΜΠ. BblXOfl neňKOflHTOB COCTaBnHeT 5x10 ππετοκ c 1 nHTpa kpobh ηπη 80% οτ hx κορτική coflepaiaHHH b flenbHOň kpobh. Hh-flyKflHIO H 6HOCHHTe3 ΗΗΤ ρ ρ ρ 3 3 Κ Κ Κ Κ Κ Κ Κ e 3 3 3 3 3 3 3 3 3 A6 A6 1 1 1 1 HT HT HT HT HT HT HT HT * * ÍIpHMep 4.

KpoBb οτ flOHopoB coČHpároT b nnacTHKOBbie naxeTbi Tuna 'TeMaKOH "coflepacaflHeUHTpaŤHbiň eTa6KrtH3aTop, Cpaay nocne c6opa xposb u eHTpn (i) yrHpyioT πρκ 2000 -tlOOg b τεηβΗΗβ 40í5 MHHyT πρκ + 4 * C c nenbio OTfleneHHH nna3Mbi οτ apHTpoflHToB.Ilocne yflaneHHH nna3Mbi co6npaioT BepxHHe 2.3 oCteMa spHTpoflHTapHoň Maccbi h cycneHflHpyroT PE-b-50 oS BEMAX NE ^ Cl. CMecb BbiflepscHBaror 10 MHHyT NPH + 4EC fleHT- h (150 g NPH JjyrHpyioT b TeneHne 20 MHHyT. nonyneHHbiň ocapoK κπετοκ pecycneHflHpy ROT b ΠΗΤβτεπΒΗοή CPEP; nanana MnanaEMEMlep% %ň% neno %enec %ň%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% %HTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHTHT 4HT 4 4 4 τ τ K K K K K K K K we K n K K K K K K K K K K c c c c c c c c c c Π Π

KpoBb οτ flOHopoB coSHparoT b nnacTHKOBbie πβκετΜ Tnna "ΓβΜβκοΗ1 'coflěpacaflHeAHTpaTHbiň cTa6nnH3aTop. Cpaay nocne oTÓopa κροββ ΗεήτρΗφντΗρνιοτ πρκ 1500 gigabytes τεηεΗΗβ '90 MHH. Πρκ 4 C C nenbro OTfleneHHH nna3Mbi οτ spHTpoflHTOB. NocneyflaneHHH nna3Mbi coĎHpawT BepxHHe 75% o6beMa apHTpoflHTapHoň Macau h peeycneH- flnpyioT ee b 3 o &amp; beMax 0.84% NH 4 Cl, BbiflepwHBakiT CMecb npH + 4tfC 20 MHHyT hfleHTpHpyioT npH 250g β τεηεΗΗε 20 MHHyT. τεηβΗΗθ20 MHHyT. OcaflOK neňKOflHTOB pecycneHflHpyroT b riHTaTenbHoň cpefle flo KOHeflfloňKOHfleHTpaflHH 10? κπ / μπ. Bbixofl neňKOflHTOB cocTaBnneT 3χ10 κπετοκ * c 1 nHTpakpobh ηπη 50% οτ o6mero coflepacaHHH β αθηβηοη kpobh. HHflyKflHio η 6nocHHTe3ΗΗτερφεροκε προβοαητ τθκ we KaK β npHMepe first 6 A6conioTHbiíí Bbixofl Η ΗτερφεροΗ3 c 1 niiTpa kpobh cocTaBnneT 6x10 ΜΕ.

KpoBb οτ flOHopoB coĎHpaioT β nnacTHKOBbie naxeTbi THna nreMaKOH "coflepaca-me RHŤpaTHbiň cTa6nnH3aTop. CPAE nocne c6opa KpoBb ΑβΗτρκφνΓΗρνιοτ πρκ5000g β τεηεΗΗε MHHyT NPH 10 4 * 0 c flenbio OTfleneHHH tina3Mbi οτ apHTpoflHTap- Maccbi Hon. Nocne yflaneHHH nna3Mbi co6Hparor BepxHHe 30% oSteMa spHTpoflHTapHoň

Maccbi h pecycneHflHpyroT β 3 o &amp; beMa. 0.80% NH4 Cl, ΑβΗτρκφνΓΗρνιοτ ripn 250g bTeneHHe 20 MHHyr h ocafloK neňKOflHTOB pecycneHRHpyioT ποΒτορΗΟ b 10 oCteMax0,83% NH4 Cl. JleftKÓflHTbi ocaacflawT ΑβΗτρκφνΓΗροΒβΗΗεΜ πρκ 150 g b Tenemie 20 MH-H HYT pecycneHflHpyroT nHTaTenbHOň cpefle.'Bbixofl neňKOflHTOB b c 1 nHTpa kpobhcoc.TaBnneT 5 xlO9 κηβτοκ ηπη 80% οτ hx eight sets coflepacaHHH b flenbHOň kpobh.HHflyKflHio η 6ηοοηητθ3 ΗΗΤβρφβροΗβ προβοαητ so ace KaK β npHMepe first A6conroTHbiň BbiKpfl ΗΗΤβρφβροΗβ C 1 nHTpa kpobh cocTasnaeT 3xlOe ME npeflnoMeHHbiň cnoc © πο3Βθππβτ hobmchtL · Bbixofl fleneBoro npoflyKTa flo 10- 12 * · l0tf ME / n KpOBH ΠΟ CpaBHeHHIO C HSBeCTHblM CnOCOSOM 4'10 * ME / Λ KpOBH.

ΦΟΡΜΥΕΑ H30BPETÉHHH «

Cnoco6 nonyneHHH HenosenecKoro neňKoflHTapHoro ΗΗτερφεροΗβ nyTGM ιχβΗτρΗ- ^ yrHpoeaHHH flOHopcKoň kpobh, OTfleneHHH neňKOflHTOB, reMonH3a ocTaroMHbix 260,968 -4- apHTpoqHTOB xnopucTbiM θμμοηηθμ, pecycneHflHpoBaHHH ocaflKa neňKOflHŤOB b πητη-TenbHoň cpefle Hma, BbifleneHHH neneBoro npoflyKTa, OTnHnatomHňcH τβΜ, ητο, cuejibio noBbnueHHB Bbixofla peneBoro npoflyKTa , iíeHTpmjjyrupoBaHHG penbHoíí kpobhocymecTBjíHioT πρκ 1500-5000 g b TeneHHe MHHyT 35 to 45, 30 to 75% oT6nparoT o6i> eMaBepxHeft nacTH ňeňKOflHTCoflepxcameň apHTpouHTHoň Maccbi, reMonH3 ocymecTBnntoT0,80-0,84% pacTBopoM xnopHfla ημμοηηη πρκ cooTHomeHHH 1: (3-50). HCTOHHHKH ΗΗφορΜΗΐχΗΗ, npHHHTbie BO BHHMaHHe πρκ 3KcnepTH3e: 1. AHanor-ConoBbeB B.fl., ΕβκτβΜΗροΒ Γ.Α. "ΗϋτερφβροΗ b τεορκπ h npaKTHKeMeflHyHHb", M., 1970. 2. ΠροτοτΗΠ In: Human Interferon Kauppinen H.-U., Myllyly '' G, - 6, 1978p. 1-13.

PE Φ EPAT

CnOCOE ΠΟΗΥΗΕΗΗΗ HEJIOBEHECKOrO ΠΕΗΚΟΗΗΤΑΡΗΟΓΟ ΗΗΤΕΡΦΕΡΟΗΑ

HacToainee θ3θ6ρετβΗΗε othochtch to oSnacTH npoMbmmeHHoft © ηοπογηη.

CnocoS nonyneHHH nenoBenecKoro neňKopHTapHoro ΗΗτερφθροΗΗ coctoht b fleHT p ^ yrHpoBaHHH ROHopcKoň kpobh r / jejieHHH JieňKouHTOB, reM0JiH3e ocTaTonHbixSpHTpOflHTOB XflOpHCTbIM aMMOHHeM, pecycneHflHpOBaHHH ocaflKa neňKOflHŤOB B-ΠΗΤ3 TenbHoň cpefle Hma, BbifleneHHH peneBoro npoflyKTa, Hobmm ΗΒηπετοΗ το, ητοΗεΗτρκφνΓΗροΒ3Ηκβ HenbHoň kpobh ocyinecTEnnioT πρκ 1500-5000 g b TeneHHe 35-45 MHHyT, oTSHpaiOT 30-75% oSteMa BepxHeft nacTH neňKOflHTCoflep®ameft spHTpoflHT · I hoh Maccbi, reMonH3. ocymecTBnntoT 0.80-0.84% pacTBopoM xnopnfla ημμοηηη πρκjcooTHomeHHH 1: (3-50). IIpH3HaHo H3o6peTeHHeM no pe3ynbraTaM 3KcnepTH3bi, ocymecTBneHHoft FocypapcT-BeHHbíM CPοΜΗΤβτοΜ CCCP nó .nenaM H3o6peTeHHn η οτκρΜτκή, 260968

Claims (1)

-5- pSeDMŽT vynálezu Způsob výroby lidského leukocytárního interferonu odstře-děním dárcovaké krve» oddělením leukooytů hernolýzou zbývají-cích erytrocytů chloridem amonným, resuspendování usazenýohleukooytů v živné půdě podle Eagla oddělením cílového pro-duktu, vyznačující se tím, že za účelem zvýšení výtěžku pro-duktu se provede odstředění použité krve při 1500 až 5000 gpo dobu 35 až 45 minut odebírání 30 až 75 % objemu vrchníčásti leukooyty obsahující hmoty erytrocytů, provede se he-rno lýza 0,80 až 0,84 % roztokem chloridu amonného při poměru1 : /3 až 50/. 260968SUMMARY OF THE INVENTION A process for the production of human leukocyte interferon by centrifuging donor blood by separating leucocyte by hermolysis of the remaining erythrocytes with ammonium chloride, resuspending the sedimented ileucoyls in an eagle broth by separating the target product, The blood is centrifuged at 1500-5000 g for 35-45 minutes to collect 30-75% of the leucoacetate-containing upper part of the erythrocyte mass, followed by a 0.80 to 0.84% ammonium chloride solution at a ratio of 1: 3. to 50 /. 260968
CS843139A 1984-04-27 1984-04-27 A method for producing human leukocyte interferon CS260968B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CS843139A CS260968B1 (en) 1984-04-27 1984-04-27 A method for producing human leukocyte interferon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS843139A CS260968B1 (en) 1984-04-27 1984-04-27 A method for producing human leukocyte interferon

Publications (2)

Publication Number Publication Date
CS313984A1 CS313984A1 (en) 1986-12-18
CS260968B1 true CS260968B1 (en) 1989-01-12

Family

ID=5370587

Family Applications (1)

Application Number Title Priority Date Filing Date
CS843139A CS260968B1 (en) 1984-04-27 1984-04-27 A method for producing human leukocyte interferon

Country Status (1)

Country Link
CS (1) CS260968B1 (en)

Also Published As

Publication number Publication date
CS313984A1 (en) 1986-12-18

Similar Documents

Publication Publication Date Title
Muller-Eberhard et al. The carbohydrate of γ-globulin and myeloma proteins
Hyun et al. Two-stage microfluidic chip for selective isolation of circulating tumor cells (CTCs)
Osserman A modified technique of immunoelectrophoresis facilitating the identification of specific precipitin arcs
Quah et al. The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation
Britton et al. The complement system in rheumatoid synovitis. II. Intracytoplasmic inclusions of immunoglobulins and complement
ES433929A1 (en) Reagent and method for determining leukocytes and hemoglobin in the blood
FR2394594A2 (en) ANAEROBIC PRESSURE SENSITIVE ADHESIVES
IL80082A0 (en) Hybrid cell line producing monoclonal antibodies and a method of assaying leukocyte concentration in blood
Behzad et al. A new anti-erythrocyte antibody in the Duffy system: anti-Fy4
Weiss et al. Ribonucleic acid within the cellular peripheral zone and the binding of calcium to ionogenic sites
ATE44824T1 (en) METHODS FOR DELIMINATION AND SEPARATION OF CELLS IN CENTRIFUGATED BLOOD SAMPLES.
CS260968B1 (en) A method for producing human leukocyte interferon
US5068175A (en) Method of detecting ras oncogene related malignancies
Lee et al. Blood component separation in straight microfluidic channels
ATE12189T1 (en) COMPOSITIONS FOR SEPARATING ERYTHROCITES FROM SERUM OR PLASMA IN BLOOD ANALYSIS SAMPLES AND METHODS FOR THEIR USE.
Banovitz et al. Precipitin Production in Chickens: XVIII. Physical Chemical Studies on Complexes of Bovine Serum Albumin and Its Chicken Antibodies
DE10122806A1 (en) Method for the detection of blood cell antigens and antibodies directed against them
Schrohenloher et al. Ultracentrifugal Studies of the Reaction of IgM Anti-γ-Globulin Subunits with Human IgG
Fry Correction: Ultrasonic Lesions in Mammalian Central Nervous System
ATE316244T1 (en) WHOLE BLOOD IMMUNOASSAY
Dunsford et al. An A4cDue/cde blood in an English family
MacIlroy et al. Anti‐Lu8, an antibody recognizing another Lutheran‐related antigen
Suzuki et al. Subtyping of factor B by agarose gel electrophoresis
NAKAMURA et al. The Principle of “Crossing” Paper Electrophoresis and Its Application to the Detection of Enzyme-Substrate Complexes and of Antigen-Antibody Reactions
Langer et al. Concomitant presence of two distinct clones of chronic lymphocytic leukemia and plasma cell myeloma in a patient